Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 2:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 245 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: CC Condition Clear all
Completed Not applicable Interventional Results available

Treatment of Pregnant Women With OUD

NCT04240392
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Collaborative Care (CC), Extension for Community Healthcare Outcomes (ECHO)
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years and older · Female only
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
11
States / cities
Hartford, Connecticut • New Britain, Connecticut • New Haven, Connecticut + 7 more
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Oct 18, 2026, 2:23 AM EDT
Completed Not applicable Interventional

Faith-based Approaches in the Treatment of Hypertension (FAITH)

NCT01065831
View directory record Official record
Conditions
Hypertension
Interventions
Motivational interviewing (MINT-TLC)
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
373 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 1, 2016 · Synced Oct 18, 2026, 2:23 AM EDT
Completed Phase 4 Interventional

Safety of Low Dose IV Contrast CT Scanning in Chronic Kidney Disease

NCT02476526
View directory record Official record
Conditions
Chronic Kidney Disease, Pulmonary Embolism, Renal Artery Stenosis, Pulmonary Cancer
Interventions
Low Volume iso-osmolar non-ionic radio contrast medium, Acetylcysteine Inhalation, Sodium Bicarbonate Solution, 64-MDCT Scanning
Drug · Procedure
Lead sponsor
VA Greater Los Angeles Healthcare System
Federal
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 28, 2017 · Synced Oct 18, 2026, 2:23 AM EDT
Completed Not applicable Interventional

Genetic Effect on Omega 3 Fatty Acids for the Treatment of Fatty Liver Disease

NCT01556113
View directory record Official record
Conditions
Non Alcoholic Fatty Liver Disease, Steatohepatitis, Hypertriglyceridemia, Alanine Aminotransferase, Plasma Level of, Quantitative Trait Locus 1
Interventions
Omega diet
Other
Lead sponsor
Yale University
Other
Eligibility
10 Years to 19 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 28, 2017 · Synced Oct 18, 2026, 2:23 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Standard Endoscopic Hemostasis Versus OVESCO Severe Non-variceal UGI Hemorrhage

NCT03065465
View directory record Official record
Conditions
Upper Gastrointestinal Hemorrhage
Interventions
Over-the-scope hemoclipping device, Standard endoscopic treatment
Device · Other
Lead sponsor
CURE Digestive Diseases Research Center
Other
Eligibility
18 Years to 100 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2025
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 27, 2024 · Synced Oct 18, 2026, 2:23 AM EDT
Completed Not applicable Interventional

The Whole Health Study: Collaborative Care for OUD and Mental Health Conditions

NCT04245423
View directory record Official record
Conditions
Opioid-use Disorder, Mental Health Conditions
Interventions
Collaborative Care for Opioid Use Disorders and Mental Health Conditions, Augmented Usual Care, Collaborative Care for Opioid Use Disorders and Mental Health Conditions Plus Certified Recovery Specialists
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
567 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Oct 18, 2026, 2:23 AM EDT
Withdrawn No phase listed Observational

Mechanisms and Predictors of Unusual Radiation or Chemotherapy Toxicity

NCT02469194
View directory record Official record
Conditions
Severe or Mild Toxicity From Radiotherapy and/or Chemotherapy
Interventions
Blood Draw
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 11, 2019 · Synced Oct 18, 2026, 2:23 AM EDT
Completed Phase 1 Interventional

Safety Study of Bone Marrow Cell Concentrate Prepared Using the Magellan System to Treat Critical Limb Ischemia (CLI)

NCT01386216
View directory record Official record
Conditions
Critical Limb Ischemia (CLI), Peripheral Vascular Disease (PVD)
Interventions
Magellan®
Device
Lead sponsor
Arteriocyte, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 24, 2017 · Synced Oct 18, 2026, 2:23 AM EDT
Recruiting Phase 2 Interventional

Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer

NCT03977233
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma (PDAC), Cancer of Pancreas, Pancreatic Cancer, Adult, Pancreas Adenocarcinoma, Pancreatic Neoplasms, Pancreatic Cancer Non-resectable, Pancreatic Cancer Resectable
Interventions
Oxaliplatin, Leucovorin, Irinotecan Hydrochloride, 5-FU
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 99 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Oct 18, 2026, 2:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Metabolism and Excretion of [14C]-CC-92480 in Healthy Male Participants

NCT04560738
View directory record Official record
Conditions
Healthy Volunteers
Interventions
[14C]-CC-92480
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 29, 2021 · Synced Oct 18, 2026, 2:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating the Effects of Food, Cytochrome P450 Inhibition and Induction on the Pharmacokinetics of CC-122

NCT03340662
View directory record Official record
Conditions
Healthy Volunteer
Interventions
CC-122, Itraconazole, Fluvoxamine, Rifampin
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 55 Years
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 16, 2019 · Synced Oct 18, 2026, 2:23 AM EDT
Completed Phase 1 Interventional

Dual Sympathetic Blocks for Patients Experiencing Sympathetically-Mediated Symptoms From Long COVID

NCT05638620
View directory record Official record
Conditions
Post Acute COVID-19 Syndrome, Long COVID, Long Covid19, COVID-19 Recurrent, Post-Acute COVID-19, Post-Acute COVID-19 Infection, SARS-CoV2 Infection, Post Acute Sequelae of COVID-19, Dysautonomia, Dysautonomia Like Disorder, Dysautonomia Orthostatic Hypotension Syndrome, Post COVID-19 Condition, Post-COVID Syndrome, Post COVID-19 Condition, Unspecified, Post-COVID-19 Syndrome
Interventions
stellate ganglion block with 0.5% bupivacaine
Drug
Lead sponsor
Jonathann Kuo, MD
Other
Eligibility
18 Years to 100 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Oct 18, 2026, 2:23 AM EDT
Completed No phase listed Observational Results available

Patient-Centered Heart Failure Trial

NCT00461513
View directory record Official record
Conditions
Heart Failure, Congestive
Interventions
Intervention
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
384 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
4
States / cities
Palo Alto, California • Denver, Colorado • Richmond, Virginia + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2018 · Synced Oct 18, 2026, 2:23 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Delphinus SoftVue Prospective Case Collection - ARM 1

NCT03257839
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Routine Full-Field Digital Mammography, Routine Digital Breast Tomosynthesis, Automated Whole Breast Ultrasound
Device
Lead sponsor
Delphinus Medical Technologies, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
7,409 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
10
States / cities
Los Angeles, California • Miami Beach, Florida • Savannah, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2021 · Synced Oct 18, 2026, 2:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Reducing Inequities in Care of Hypertension, Lifestyle Improvement for Everyone (RICH LIFE Project)

NCT02674464
View directory record Official record
Conditions
Uncontrolled Hypertension
Interventions
Provider Audit-Feedback, Stratified by Race and Ethnicity, Blood Pressure Measurement Standardization, System Level Leadership Intervention, Collaborative Care Team Intervention, Community Health Worker Referral, Specialist Care Consultation
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 100 Years
Enrollment
1,820 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2022 · Synced Oct 18, 2026, 2:23 AM EDT
Recruiting Phase 2 Interventional

Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer

NCT06145633
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Bone Scan, Computed Tomography, Fludeoxyglucose F-18, Gallium Ga 68 Gozetotide, Lutetium Lu 177 Vipivotide Tetraxetan, Positron Emission Tomography, Single Photon Emission Computed Tomography, Vorinostat
Procedure · Other · Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 18, 2026, 2:23 AM EDT
Withdrawn Early Phase 1 Interventional

Melphalan on Disease Burden Measured by Next Generation Sequencing Before AHCT (Autologous Hematopoietic Cell Transplant) for Multiple Myeloma

NCT05013437
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Evomela, Next Generation Sequencing, Prochlorperazine, Acetaminophen, Diphenhydramine
Drug · Device
Lead sponsor
Koen van Besien
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 2, 2024 · Synced Oct 18, 2026, 2:23 AM EDT
Completed Not applicable Interventional

Safety and Efficacy of PRP for Treatment of Disc Pain

NCT04064866
View directory record Official record
Conditions
Discogenic Pain
Interventions
High yield pure PRP, Placebo, ProPlaz PPC
Device · Other
Lead sponsor
Neurological Associates of West Los Angeles
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
7
States / cities
Campbell, California • Santa Monica, California • Peachtree City, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2019 · Synced Oct 18, 2026, 2:23 AM EDT
Not yet recruiting Phase 1 Interventional

Escalating Cycle 1 Dose of Lu-177-PSMA-617 for the Treatment of Metastatic Castration Resistant Prostate Cancer

NCT07682649
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Gallium Ga 68 Gozetotide, Lutetium Lu 177 Vipivotide Tetraxetan, Positron Emission Tomography, Questionnaire Administration, Single Photon Emission Computed Tomography, Technetium Tc-99m Sulfur Colloid
Procedure · Other · Drug + 1 more
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 18, 2026, 2:23 AM EDT
Completed No phase listed Observational

Safety & Efficacy Study of the Medtronic CoreValve® System-Treatment of Symptomatic Severe Aortic Stenosis With Significant Comorbidities in Extreme Risk Subjects Who Need Aortic Valve Replacement

NCT01675440
View directory record Official record
Conditions
Severe Aortic Stenosis
Interventions
Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)
Device
Lead sponsor
Medtronic Cardiovascular
Industry
Eligibility
Not listed
Enrollment
782 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2025
U.S. locations
43
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 33 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 18, 2026, 2:23 AM EDT
Terminated Phase 4 Interventional Results available

Study Evaluating The Safety Of Xyntha In Usual Care Settings

NCT00765726
View directory record Official record
Conditions
Hemophilia A
Interventions
Moroctocog alfa(AF-CC), Blood draw for laboratory testing
Biological · Procedure
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
5
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2012 · Synced Oct 18, 2026, 2:23 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

NCT01522976
View directory record Official record
Conditions
Chronic Myelomonocytic Leukemia, Chronic Myelomonocytic Leukemia-1, Chronic Myelomonocytic Leukemia-2, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts, Myelodysplastic Syndrome With Excess Blasts-1, Myelodysplastic Syndrome/Acute Myeloid Leukemia
Interventions
Azacitidine, Laboratory Biomarker Analysis, Lenalidomide, Vorinostat
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2027
U.S. locations
280
States / cities
Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 217 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 18, 2026, 2:23 AM EDT
Terminated Phase 1 Interventional

Safety, Tolerability and Preliminary Efficacy of Adipose Derive Stem Cells for Patients With COPD

NCT02161744
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
ADSCs administration
Biological
Lead sponsor
Arkansas Heart Hospital
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
2
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Oct 18, 2026, 2:23 AM EDT
Active, not recruiting No phase listed Observational

Neuropsychiatric Post-Acute Sequelae of SARS-CoV-2 (PASC) Using TSPO Positron Emission Tomography (PET) and MRI

NCT05615415
View directory record Official record
Conditions
Neuropsychiatric Post-Acute Sequelae of SARS-CoV-2 Infection
Interventions
PET Tracer, MRI Tracer, 3T PET/MRI
Drug · Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Timeline
2022 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 18, 2026, 2:23 AM EDT